BPC-157 and TB-500: Your Questions, Answered from the Record

Side effects, safety, and the tumor question

What are the side effects of BPC-157 and TB-500?

Long-term human safety is unknown for both constituents and the blend. The principal documented concern is a tumor signal: Thymosin Beta-4 is implicated in metastasis and tumor angiogenesis, so the same pro-angiogenic, pro-migratory properties that aid repair could theoretically support tumor progression ^[7]. Combining two unapproved peptides doubles the uncertainty rather than halving it.

Does TB-500 cause cancer or promote tumor growth?

Thymosin Beta-4 has been implicated in tumor metastasis and angiogenesis in tumor models; this is a theoretical safety consideration, not a demonstrated cancer-causing effect of TB-500 in humans ^[7]. No human data establish either safety or harm for the TB-500 fragment in this respect. It is a reason for caution and honest labelling, not a settled finding.

Is TB-500 bad for your heart?

Human intravenous full-length Thymosin Beta-4 was well tolerated to 1260 mg with no dose-limiting toxicities in a Phase 1 study ^[7]. However, no controlled cardiac-safety data exist for the TB-500 heptapeptide or the blend, and an mdx-mouse study showed no cardiac-function improvement ^[7]. The reassuring datum is for the full protein given intravenously; it does not transfer cleanly to the fragment or the blend.

What the blend is, and what it is studied for

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin Beta-4 ^[6]. The "Wolverine" blend pairs the two as a research-community tissue-repair stack with no standardized ratio.

What is the Wolverine peptide blend?

A research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair "stack." It is not a single chemical entity, has no CAS number or standardized ratio, and is not an approved product anywhere ^[8].

What is the BPC-157 and TB-500 blend used for in research?

Preclinical (mostly rodent) research on the two constituents covers tendon, ligament, muscle, and bone repair, wound and soft-tissue healing, cytoprotection, and angiogenesis ^[5][7]. These are single-compound, animal-model findings; the blend itself has no controlled efficacy study.

What is the difference between BPC-157 and TB-500?

They are structurally unrelated. BPC-157 is a 15-amino-acid pentadecapeptide from a gastric-juice protein acting via VEGFR2/nitric-oxide and growth-hormone-receptor pathways ^[1][3]; TB-500 is a 7-amino-acid acetylated fragment of Thymosin Beta-4 acting by sequestering G-actin ^[6]. Different sequences, sizes, and mechanisms.

How they work and why they are combined

How does BPC-157 work compared to TB-500?

BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS up-regulation, nitric-oxide modulation, growth-hormone-receptor sensitization of tendon fibroblasts) ^[1][3]. TB-500 supplies an intracellular actin-sequestration signal, binding monomeric G-actin 1:1 via the LKKTETQ motif to regulate cell migration ^[6]. The two are described as complementary but largely non-overlapping.

How does TB-500 work (actin / Thymosin Beta-4)?

TB-500 is the Ac-LKKTETQ fragment of Thymosin Beta-4. X-ray crystallography established that Thymosin Beta-4 forms a 1:1 complex with monomeric G-actin and sequesters it by capping both ends, regulating the cytoskeletal dynamics that drive cell migration ^[6] — the complementary half of the blend's mechanism alongside BPC-157's cytoprotection.

Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?

In preclinical models, by separate routes: BPC-157 up-regulates VEGFR2 and promotes its internalization with downstream Akt-eNOS signaling (increased vessel density and faster blood-flow recovery in ischemic rat muscle) ^[1], and modulates vasomotor tone through a Src-Caveolin-1-eNOS pathway ^[2]; Thymosin Beta-4 (TB-500's parent) promotes endothelial-migration angiogenesis ^[7]. No controlled combination study has measured a combined angiogenic effect.

Do BPC-157 and TB-500 act through the same pathway?

No. BPC-157 acts on VEGFR2-Akt-eNOS / nitric-oxide and growth-hormone-receptor signaling in fibroblasts ^[1][3]; TB-500 acts on the cytoskeleton by sequestering monomeric G-actin ^[6]. The "synergy" rationale rests on these being complementary, non-overlapping mechanisms — it is a theoretical extrapolation, not a demonstrated combination finding.

Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The rationale is complementary mechanisms: BPC-157's local cytoprotective and pro-angiogenic signal is paired with TB-500's cytoskeletal cell-migration signal, so the two are proposed to cover different stages of tissue repair ^[1][6]. Critically, no head-to-head or combination study has defined a synergistic dose, ratio, or endpoint for the two given together.

Evidence, efficacy, and the combination gap

Is there any study showing BPC-157 and TB-500 work better together (synergy)?

No. No peer-reviewed study has defined a synergy ratio, dose, or endpoint for the two given together. A 2025 systematic review of BPC-157 (36 studies, only 1 human, "no clinical safety data") makes no mention of TB-500 or combination use ^[9]. "Synergy" is an extrapolation from each peptide's separate mechanism.

Are there human clinical trials on the BPC-157 + TB-500 combination?

None. There are no controlled clinical trials of the BPC-157 + TB-500 combination for any indication. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies; "TB-500" human data are for full-length Thymosin Beta-4, not the heptapeptide ^[9].

Does the BPC-157 TB-500 blend help tendon and ligament injuries?

In animal models, BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures and enhanced tendon-fibroblast outgrowth via FAK-paxillin signaling ^[4][5]. These are preclinical, single-compound results, not human or combination evidence.

Does BPC-157 and TB-500 help muscle tears and recovery?

Preclinical studies report BPC-157 aiding muscle and tendon repair through cytoprotective and growth-hormone-receptor mechanisms ^[3]; Thymosin Beta-4 (TB-500's parent) supports cell migration ^[7]. Findings are animal-model and single-compound; the blend has no controlled muscle-recovery trial.

Does the BPC-157 TB-500 blend help wound healing?

In animal wound models, Thymosin Beta-4 (TB-500's parent) increased re-epithelialization, contraction, collagen deposition, and angiogenesis, and BPC-157 shows multi-tissue cytoprotection ^[5][7]. These are preclinical, single-compound results; the blend itself has no controlled wound-healing trial.

Dosing, handling, and pharmacokinetics

What is the half-life of BPC-157 and TB-500?

No validated human half-life exists for either constituent or the blend. BPC-157's elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study; human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide ^[7].

How do you reconstitute a BPC-157 / TB-500 blend (10mg)?

Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated ^[8]. Product identity, purity, and the actual BPC-157-to-TB-500 ratio in unregulated material are not guaranteed. This is research-handling context, not a human-use instruction.

How often should you inject BPC-157 and TB-500?

There is no validated injection schedule for the blend. Underlying rodent studies used a range of dosing (for example, Thymosin Beta-4 at 150 microg twice weekly intraperitoneally for six months in one model) ^[7]; community "loading then maintenance" protocols have no controlled-trial basis ^[8].

How do you cycle BPC-157 and TB-500?

No validated cycle exists. Community "loading then maintenance" blend protocols and fixed-ratio vials (for example, 10 mg plus 10 mg) have no basis in controlled human trials and should not be presented as validated dosing ^[8]. Underlying study durations vary widely by model.

Legal status and anti-doping

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither constituent is FDA-approved and the blend has no approved indication. The FDA placed BPC-157 in Category 2 — bulk substances that may present significant safety risks, not eligible for routine 503A compounding — effective the September 29, 2023 list update, and did the same for the thymosin beta-4 fragment (LKKTETQ), TB-500 ^[12]. Both are WADA-prohibited (BPC-157 under S0; TB-500 / thymosin beta-4 under prohibited peptide and growth-factor categories) ^[8].

Is Wolverine legal?

The blend is two unapproved research peptides, not a finished drug, so there is no single yes-or-no. Neither BPC-157 nor TB-500 is FDA-approved, and both are currently Category 2 bulk substances — not eligible for routine 503A compounding today — while both sit on the scheduled July 23-24, 2026 FDA advisory-committee agenda ^[12][14]. This is general regulatory information, not legal advice.

Can you get BPC-157 from a compounding pharmacy?

Under current FDA policy, BPC-157 is not eligible for routine 503A compounding: it is a Category 2 bulk substance, outside the enforcement-discretion policy ^[12][13]. Its status is on the agenda for the July 23-24, 2026 PCAC meeting as a 503A bulks-list candidate — a scheduled discussion, not a decision ^[14]. Lawful compounded access generally requires a licensed-prescriber evaluation, a valid prescription, and an eligible ingredient ^[21].

What is the FDA 503A status of Wolverine?

The blend has no 503A status of its own; the question resolves to its ingredients. Both BPC-157 and TB-500 are Category 2 bulk substances as of the September 29, 2023 list update, so neither is eligible for routine 503A compounding ^[12]. Both are listed on the July 23-24, 2026 PCAC agenda as candidates for the 503A bulks list — under active review, not reclassified ^[14].